Lexicon Pharmaceuticals (LXRX) EBITDA (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported EBITDA for 17 consecutive years, with -$996000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA rose 96.12% year-over-year to -$996000.0; the TTM figure through Mar 2026 stood at -$24.2 million (up 86.35% YoY), while the FY2025 annual figure was -$48.9 million, up 75.19% from the prior year.
• EBITDA improved to -$996000.0 in Q1 2026 per LXRX's latest filing, from -$14.8 million in the prior quarter.
• Across five years, EBITDA topped out at $3.7 million in Q2 2025 and bottomed at -$63.7 million in Q3 2024.
• Historically, EBITDA has averaged -$30.6 million across 5 years, with a median of -$30.3 million in 2022.
• Annual changes were most pronounced in 2023 — EBITDA tumbled 114.9% — and 2025, when it surged 106.75%.
• Lexicon Pharmaceuticals' EBITDA stood at -$30.3 million in 2022, then sank by 54.36% to -$46.7 million in 2023, then advanced by 29.95% to -$32.7 million in 2024, then surged by 54.85% to -$14.8 million in 2025, then surged by 93.26% to -$996000.0 in 2026.
• Business Quant data shows LXRX's EBITDA at -$996000.0 in Q1 2026, -$14.8 million in Q4 2025, and -$12.2 million in Q3 2025.